Finasteride delays atherosclerosis progression in mice and is associated with a reduction in plasma cholesterol in men
Journal of Lipid Research · 2024
DOI: 10.1016/j.jlr.2024.100507 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Lipid Research, 2024. Verfasst von Patrick McQueen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nutritional Sciences, University of Illinois Urbana Champaign, Urbana, IL, USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Atherosclerosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NHLBI, U.S. Department of Agriculture.
Abstract (Originalsprache)
Finasteride is commonly prescribed to treat benign prostate hyperplasia and male-pattern baldness in cis men and, more recently, trans individuals. However, the effect of finasteride on cardiovascular disease remains elusive. We evaluated the role of finasteride on atherosclerosis using low-density lipoprotein (LDL) receptor-deficient (Ldlr-/-) mice. Next, we examined the relevance to humans by analyzing the data deposited between 2009 and 2016 in the National Health and Nutrition Examination Survey. We show that finasteride reduces total plasma cholesterol and delays the development of atherosclerosis in Ldlr-/- mice. Finasteride reduced monocytosis, monocyte recruitment to the lesion, macrophage lesion content, and necrotic core area, the latter of which is an indicator of plaque vulnerability in humans. RNA sequencing analysis revealed a downregulation of inflammatory pathways and an upregulation of bile acid metabolism, oxidative phosphorylation, and cholesterol pathways in the liver of mice taking finasteride. Men reporting the use of finasteride showed lower plasma levels of cholesterol and LDL-cholesterol than those not taking the drug. Our data unveil finasteride as a potential treatment to delay cardiovascular disease in people by improving the plasma lipid profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nutritional Sciences, University of Illinois Urbana Champaign, Urbana, IL, USA.
- Department of Food Science and Human Nutrition, University of Illinois Urbana Champaign, Urbana, IL, USA.
- Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, USA.
- Carver Metabolomics Core, Roy J. Carver Biotechnology Center, University of Illinois Urbana Champaign, Urbana, IL, USA.
- Division of Nutritional Sciences, University of Illinois Urbana Champaign, Urbana, IL, USA; Department of Food Science and Human Nutrition, University of Illinois Urbana Champaign, Urbana, IL, USA. Electronic address: j…
Förderung
- NHLBI NIH HHS
- NHLBI
- U.S. Department of Agriculture
- USDA NIFA
- National Institutes of Health
Zitieren
APA
McQueen, P., Molina, D., Pinos, I., Krug, S., Taylor, A. J., LaFrano, M. R., Kane, M. A., & Amengual, J. (2024). Finasteride delays atherosclerosis progression in mice and is associated with a reduction in plasma cholesterol in men. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2024.100507
Vancouver
McQueen P, Molina D, Pinos I, Krug S, Taylor AJ, LaFrano MR, et al. Finasteride delays atherosclerosis progression in mice and is associated with a reduction in plasma cholesterol in men. Journal of Lipid Research. 2024. doi:10.1016/j.jlr.2024.100507
BibTeX
@article{McQueen2024,
author = {McQueen, Patrick and Molina, Donald and Pinos, Ivan and Krug, Samuel and Taylor, Anna J and LaFrano, Michael R and Kane, Maureen A and Amengual, Jaume},
title = {Finasteride delays atherosclerosis progression in mice and is associated with a reduction in plasma cholesterol in men},
journal = {Journal of Lipid Research},
year = {2024},
doi = {10.1016/j.jlr.2024.100507}
}
EUVIMED